BRL-303 / BRL Medicine - LARVOL DELTA

ALLOGENEIC CD19-TARGETED CAR-T THERAPY FOR REFRACTORY MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (EHA 2025) - P=N/A | "Participants were screened and underwent lymphodepletion chemotherapy with cyclophosphamide (300 mg/m², day -5 to -4) and fludarabine (25 mg/m², day -5 to -3), then BRL-303 infusion at day 0 with a dose level of 1×106 cells/kg...All of them developed grade 1 CRS for 2 or 3 days, which recovered soon without tocilizumab and steroid usage... Overall, SLE subjects treated with BRL-303 achieved significant clinical remission, with a controllable safety profile, offering a potential paradigm shift for SLE patients who are refractory to currently available treatments. Further observation of SLE and more autoimmune disorders treated with BRL-303 are ongoing in our studies."

Fatigue • Glomerulonephritis • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Neutropenia • Renal Disease • Systemic Lupus Erythematosus

Allogeneic CD19-targeted CAR-T Therapy for refractory Systemic Lupus Erythematosus (SLE) (ASGCT 2025) - P=N/A | "Participants were screened and underwent lymphodepletion chemotherapy with cyclophosphamide (300 mg/m², day -5 to -4) and fludarabine (25 mg/m², day -5 to -3), then BRL-303 infusion at day 0 with a dose level of 1×106 cells/kg...All of them developed grade 1 CRS for 2 or 3 days, which recovered soon without tocilizumab and steroid usage... Overall, SLE subjects treated with BRL-303 achieved significant clinical remission, with a controllable safety profile, offering a potential paradigm shift for SLE patients who are refractory to currently available treatments. Further observation of SLE and more autoimmune disorders treated with BRL-303 are ongoing in our studies."

Fatigue • Glomerulonephritis • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Neutropenia • Renal Disease • Systemic Lupus Erythematosus

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Xuanwu Hospital, Beijing | Initiation date: Aug 2024 ➔ Feb 2025

Trial initiation date • CNS Disorders • Immunology • Multiple Sclerosis • Myasthenia Gravis • Neuromyelitis Optica Spectrum Disorder • Pain • Rare Diseases

Allogeneic CD19-targeted CAR-T therapy for refractory systemic lupus erythematosus (SLE) (EADV 2024) - P=N/A | "Participants were screened and underwent lymphodepletion chemotherapy with cyclophosphamide (300 mg/m2, day -5 to -4) and fludarabine (25 mg/m2, day -5 to -3), then BRL-303 infusion at day 0 with a dose level of 1×106 cells/kg...In terms of safety, the patient’s vital signs remained mostly stable throughout the monitoring period, 2 subjects developed grade 1 CRS on D4 and D5, which recovered soon without tocilizumab and steroid usage... Overall, SLE subjects treated with BRL-303 achieved significant clinical remission, with a controllable safety profile, offering a potential paradigm shift for SLE patients who are refractory to currently available treatments. Further observation of SLE and more autoimmune disorders treated with BRL-303 are ongoing in our study. Figure 1 Effects of BRL-303 for SLE patient (A, SLEDAI-2K and PGA change befor and after BRL-303 treatment; B, SLEDAI-2K Score changs; C,Serological changes; D, Urine protein changes) 25 SEPTEMBER -..."

Late-breaking abstract • Glomerulonephritis • Graft versus Host Disease • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus